Skip to main content

Advertisement

Table 2 Health care services and medication utilization related to severity

From: Health care costs and resource utilization for different asthma severity stages in Colombia: a claims data analysis

  Total
n = 20,410
Mild
intermittent
n = 14,191
Mild
Persistent
n = 3680
Moderate Persistent
n = 1408
Severe persistent
n = 1131
p-valuea
Medical services (n, %)b
 ED visits* 721 (3.5) 462 (12.5) 163 (11.5) 96 (8.5) < 0.001
  Mean (SD)c 1.1 (0.5) 1 (0) 1.3 (0.5) 1.4 (1.1)  
 Hospitalizations* 1137 (5.5) 495 (13.4) 278 (19.7) 364 (32.1) < 0.001
  Mean (SD)c 1.6 (1.6) 1 (0) 1.5 (0.6) 2.5 (2.6)  
 Specialized physician visits 5764 (28.2) 3539 (24.9) 1057 (28.7) 578 (41.0) 590 (52.1) < 0.001
 General physician visits 11,685 (57.2) 8445 (59.5) 1761 (47.8) 755 (53.6) 724 (64.1) < 0.001
 Other ambulatory services 1653 (8.1) 1009 (7.1) 297 (8.0) 160 (11.3) 187 (16.5) < 0.001
Total frequency of any medical service 17,059 (83.5) 11,933 (84.1) 2923 (79.4) 1167 (82.8) 1036 (91.6) 0.026
Asthma medication prescriptions (n, %)b
 Controller medications
  ICS 4841 (23.7) 1777 (12.5) 1410 (38.3) 821 (58.3) 833 (73.6) < 0.001
  ICS + LABA 487 (2.4) 32 (0.2) 88 (2.4) 171 (12.1) 196 (17.3) < 0.001
  LABA 188 (0.9) 18 (0.1) 65 (1.7) 38 (2.7) 67 (5.9) < 0.001
  LM 660 (3.2) 0 (0) 221 (6.0) 154 (10.9) 285 (25.2) < 0.001
  Theophylline 240 (1.1) 36 (0.2) 62 (1.6) 63 (4.4) 79 (6.9) < 0.001
 Rescue Medications
  Oral corticosteroids 4594 (22.5) 399 (2.8) 2236 (60.7) 998 (70.8) 961 (84.9) < 0.001
  SABA 4911 (24.0) 1242 (8.7) 1798 (48.8) 946 (67.2) 925 (81.8) < 0.001
Total frequency of any medication 9509 (46.6) 3880 (27.3) 3183 (86.5) 1336 (94.9) 1110 (98.1) < 0.001
  1. *For ED visits and hospitalizations trend analysis was conducted for mild to severe persistent categories
  2. aCochran-Armitage test. P for trend is reported
  3. bThe number of patients using each medical service is reported. Relative frequencies were calculated using the total number of subjects (N) for each column as denominator. Patients may have used more than one service in the cost analysis period
  4. cMean number of times that a patient required to use this medical service during the cost analysis period
  5. ED emergency department; ICS inhaled corticosteroids; ICS + LABA inhaled corticosteroids-long acting B2 agonist combination; LABA long acting B2 agonist; LM leukotriene modifiers; SABA short acting B2 agonist